EA199800395A1 - Производные 2-хинолона, ингибирующие фарнезилтрансферазу - Google Patents

Производные 2-хинолона, ингибирующие фарнезилтрансферазу

Info

Publication number
EA199800395A1
EA199800395A1 EA199800395A EA199800395A EA199800395A1 EA 199800395 A1 EA199800395 A1 EA 199800395A1 EA 199800395 A EA199800395 A EA 199800395A EA 199800395 A EA199800395 A EA 199800395A EA 199800395 A1 EA199800395 A1 EA 199800395A1
Authority
EA
Eurasian Patent Office
Prior art keywords
6alkyl
6alkyloxy
alkyl
amino
hydroxy
Prior art date
Application number
EA199800395A
Other languages
English (en)
Other versions
EA000719B1 (ru
Inventor
Девид Вилльям Энд
Марк Гастон Вене
Патрик Рене Анжибо
Жерар Шарль Санз
Original Assignee
Жансен Фармасетика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Жансен Фармасетика Н.В. filed Critical Жансен Фармасетика Н.В.
Publication of EA199800395A1 publication Critical patent/EA199800395A1/ru
Publication of EA000719B1 publication Critical patent/EA000719B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Настоящее изобретение относится к соединениям формулы (I)их стереохимически изомерным формам и фармацевтически приемлемым солям присоединения кислот или оснований, в которых пунктирная линия обозначает необязательную связь; X представляет кислород или серу; Rпредставляет водород, Cалкил, Ar, ArCалкил, хинолинил-Cалкил, пиридил-Cалкил, гидрокси-Cалкил, Cалкилокси-Cалкил, моно- или ди(Cалкил)амино-Cалкил, амино-Cалкил, или радикал формулы -Alk(=O)-R, -Alk-S(O)-Rили –Alk-S(O)-R; Rи R, каждый независимо представляет водород, гидрокси, галоген, циано, Cалкил, Cалкилокси, гидрокси-Cалкилокси, Cалкилокси-Cалкилокси, амино-Cалкилокси, моно- или ди(Cалкил)амино-Cалкилокси, Ar, ArCалкил, Arокси, ArCалкилокси, гидроксикарбонил, Cалкилоксикарбонил, тригалогенметил, тригалогенметокси, Cалкенил; или, находясь в смежных положениях, Rи R, взятые вместе, могут образовывать двухвалентный радикал; Rи R, каждый независимо представляет водород, Ar, Cалкил, Cалкилокси-Cалкил, Cалкилокси, Cалкилтио, амино, гидроксикарбонил, Cалкилоксикарбонил, CалкилS(О)Cалкил или CалкилS(O)Cалкил; Rи R, каждый независимо представляет водород, галоген, циано, Cалкил, CCалкилоксикарбонил, Cалкилкарбонил Cалкил, циано-Cалкил, Cалкилоксикаробонил Cалкил, гидроксикарбонил-Cалкил, гидрокси-Cалкил, амино-Cалкил, моно- или ди(Cалкил)амино-Cалкил, галоген-Cалкил, Cалкилокси-Cалкил, аминокарбонил-Cалкил, Ar, ArCалкилокси-Cалкил, Cалкилтио-Cалкил; Rпредставляет водород, Cалкил или галоген; Rпредставляет водород или Cалкил; которые обладают ингибирующей фарнезилтрансферазу активностью; к их получению, к содержащим их композициям и к их применению в качестве лекарственного средства.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199800395A 1995-10-31 1996-10-25 Производные 2-хинолона, ингибирующие фарнезилтрансферазу EA000719B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95202945 1995-10-31
PCT/EP1996/004661 WO1997016443A1 (en) 1995-10-31 1996-10-25 Farnesyl transferase inhibiting 2-quinolone derivatives

Publications (2)

Publication Number Publication Date
EA199800395A1 true EA199800395A1 (ru) 1998-10-29
EA000719B1 EA000719B1 (ru) 2000-02-28

Family

ID=8220785

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800395A EA000719B1 (ru) 1995-10-31 1996-10-25 Производные 2-хинолона, ингибирующие фарнезилтрансферазу

Country Status (29)

Country Link
US (1) US5968952A (ru)
EP (2) EP1106610B1 (ru)
JP (1) JP4257869B2 (ru)
KR (1) KR100417620B1 (ru)
CN (1) CN1101391C (ru)
AR (1) AR004699A1 (ru)
AT (2) ATE212627T1 (ru)
AU (1) AU712435B2 (ru)
CA (1) CA2231143C (ru)
CY (1) CY2287B1 (ru)
CZ (1) CZ290954B6 (ru)
DE (2) DE69618999T2 (ru)
DK (1) DK1019395T3 (ru)
EA (1) EA000719B1 (ru)
ES (2) ES2171736T3 (ru)
HK (2) HK1027576A1 (ru)
HU (1) HU224032B1 (ru)
IL (1) IL123567A (ru)
MY (1) MY116577A (ru)
NO (1) NO314037B1 (ru)
NZ (1) NZ321576A (ru)
PL (1) PL184168B1 (ru)
PT (1) PT1019395E (ru)
SI (1) SI1019395T1 (ru)
SK (1) SK282642B6 (ru)
TR (1) TR199800720T2 (ru)
TW (1) TW349948B (ru)
WO (1) WO1997016443A1 (ru)
ZA (1) ZA969087B (ru)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0988038T3 (da) * 1997-06-02 2002-12-02 Janssen Pharmaceutica Nv Anvendelse af (imidazol-5-yl)methyl-2-quinolinon derivater til hæmning af glat muskelcelleproliferation
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
HUP0100860A3 (en) * 1997-12-11 2003-03-28 Janssen Pharmaceutica Nv Retinoic acid mimetic anilides, process for their preparation and pharmaceutical compositions containing them
US6420555B1 (en) 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
DE69915835T2 (de) * 1998-06-16 2005-03-24 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Imidazol-derivate
WO2000001386A1 (en) 1998-07-06 2000-01-13 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating arthropathies
CA2336624C (en) 1998-07-06 2008-10-21 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
FR2780892B1 (fr) * 1998-07-08 2001-08-17 Sod Conseils Rech Applic Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
CA2341739C (en) * 1998-08-27 2005-07-12 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
EE200100118A (et) 1998-08-27 2002-06-17 Pfizer Products Inc. Vähivastaste vahenditena kasulikud alkünüül-asendatud kinoliin-2-ooni derivaadid
US6316436B1 (en) 1998-12-08 2001-11-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2477400A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ID29241A (id) * 1998-12-23 2001-08-16 Janssen Pharmaceutica Nv Turunan-turunan kinolin teranelasi-1,2
EP1150973B1 (en) 1999-02-11 2005-06-15 Pfizer Products Inc. Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
US6143766A (en) * 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
EP1420015A1 (en) * 1999-06-11 2004-05-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Imidazolyl derivatives
ATE259365T1 (de) 1999-11-30 2004-02-15 Pfizer Prod Inc Chinolinderivate verwendbar zur hemmung der farnesyl-protein transferase
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
EP1267848B1 (en) 2000-02-24 2007-10-17 Janssen Pharmaceutica N.V. Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer
US20030078281A1 (en) * 2000-02-29 2003-04-24 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
EP1267872A2 (en) * 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
CA2397690A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
US20030212008A1 (en) * 2000-02-29 2003-11-13 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
CA2397475A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
EP1261341A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with camptothecin compounds
CA2397349A1 (en) * 2000-02-29 2001-09-07 Ivan David Horak Farnesyl protein transferase inhibitor combinations with an her2 antibody
JP2003525246A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 白金化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
WO2001064218A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations
EP1265611A2 (en) * 2000-02-29 2002-12-18 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
EP1267871A2 (en) * 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en) * 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
JP4974439B2 (ja) * 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
ATE321038T1 (de) * 2000-09-25 2006-04-15 Janssen Pharmaceutica Nv Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
EP1322636A1 (en) * 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6- (substituted phenyl)methyl]-quinoline and quinazoline derivatives
US7153958B2 (en) 2000-11-21 2006-12-26 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
WO2002043733A1 (en) * 2000-11-28 2002-06-06 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
BR0116302A (pt) * 2000-12-19 2004-01-13 Pfizer Prod Inc Formas cristalinas de sais 2,3-dihidroxibutanodioato de 6-[(4-clorofenil)-hidróxi-(3-metil-3h-imidazol-4-il)-meti l]-4-(3-etinil-fenil)-1-metil-1h-quinolin-2-ona e método de produção
JP4351445B2 (ja) * 2000-12-27 2009-10-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する４−置換−キノリンおよびキナゾリン誘導体
EP1351954B1 (en) * 2000-12-27 2006-05-03 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives
US20040110769A1 (en) * 2001-02-15 2004-06-10 End David William Farnesyl protein transferase inhibitor combinations with antiestrogen agents
SI1373255T1 (ru) 2001-03-12 2005-08-31 Janssen Pharmaceutica Nv
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
DE60231646D1 (de) 2001-12-19 2009-04-30 Janssen Pharmaceutica Nv Durch c-verbundene imidazole substituierte 1,8-annellierten chinolon-derivate als farnesyl transferase inhibitoren
US7241777B2 (en) 2002-03-22 2007-07-10 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
US7511138B2 (en) 2002-04-15 2009-03-31 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
FR2841243B1 (fr) * 2002-06-19 2004-08-20 Servier Lab Nouveaux derives de 3-(4-oxo-4h-chromen-2yl)-(1h)-quinolein- 4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
FR2860235A1 (fr) * 2003-09-29 2005-04-01 Yang Ji Chemical Company Ltd Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
NZ584773A (en) * 2004-09-17 2012-07-27 Whitehead Biomedical Inst Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
PL2362218T3 (pl) 2004-11-05 2015-02-27 Janssen Pharmaceutica Nv Sposoby kontroli skuteczności inhibitorów transferazy farnezylowej
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20060281755A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281769A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20070004660A1 (en) * 2005-06-10 2007-01-04 Baumann Christian A Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
US7833339B2 (en) 2006-04-18 2010-11-16 Franklin Industrial Minerals Mineral filler composition
EP2545919A1 (en) 2005-12-23 2013-01-16 Link Medicine Corporation Treatment of synucleinopathies
EP2016070B1 (en) 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
SI2021335T1 (sl) 2006-04-20 2011-09-30 Janssen Pharmaceutica Nv Heterocikliäśne spojine kot zaviralci c-fms kinaze
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
DE102007015709B4 (de) 2007-01-25 2009-09-03 Webasto Ag Fahrzeugdach
MX2009013333A (es) 2007-06-05 2010-01-18 Schering Corp Derivados de indazol policiclicos y su uso como inhibidores de erk para el tratamiento de cancer.
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
WO2009117484A2 (en) * 2008-03-18 2009-09-24 University Of South Florida Small molecule e2f inhibitor
WO2010057006A1 (en) 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
US8658651B2 (en) 2009-09-30 2014-02-25 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
AU2011237642B2 (en) 2010-04-06 2014-05-01 Brigham Young University Antimetastatic compounds
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
WO2012016021A2 (en) 2010-07-28 2012-02-02 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
AU2011293449A1 (en) * 2010-08-24 2013-02-28 Brigham Young University Antimetastatic compounds
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
CN103906751A (zh) 2011-10-02 2014-07-02 波士顿大学董事会 作为晚期SV40因子（LSF）抑制剂用于治疗癌症的[1,3]二氧杂环戊烯并[4,5-g]喹啉-6(5H)-硫酮和[1,3]二氧杂环戊烯并[4,5-g][1,2,4]三唑并[1,5-a]喹啉衍生物
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
WO2014025675A1 (en) 2012-08-07 2014-02-13 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
EP3103455A4 (en) * 2014-02-07 2017-10-04 National University Corporation Tokyo Medical and Dental University Myogenesis accelerator, amyotrophy suppressor, medicinal composition, and taz activator
HUE057306T2 (hu) 2015-08-17 2022-04-28 Kura Oncology Inc Módszerek rákos páciensek kezelésére farneziltranszferáz inhibitorokkal
EP3133066A1 (en) * 2015-08-21 2017-02-22 Merck Patent GmbH Hydrophilic compounds for optically active devices
EP3133065A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Compounds for optically active devices
WO2017034877A1 (en) * 2015-08-27 2017-03-02 Janssen Pharmaceutica Nv Chemically modified quinoline and quinolone derivatives useful as cb-1 inverse agonists
EA201991091A1 (ru) 2016-11-03 2019-11-29 Способы лечения пациентов со злокачественными новообразованиями с применением ингибиторов фарнезилтрансферазы
EP3363786A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Compounds for optically active devices
EP3363793A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobic compounds for optically active devices
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3900501A (en) * 1970-12-23 1975-08-19 Hoffmann La Roche Benzophenone intermediates for 7-lower alkanoyl benzodiazepines
IL65709A (en) * 1981-05-18 1986-01-31 Chevron Res Electroactive polymers
JPS63275548A (ja) * 1987-05-02 1988-11-14 Res Inst For Prod Dev ｏ−アミノベンゾイル化合物の製造方法
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
EP0574992A1 (en) * 1992-06-17 1993-12-22 Glaxo Group Limited 5-(1,2,4-Triazol-1-ylmethyl)-3H-isobenzofuran-1-one derivatives, their preparation and use as aromatase inhibitors
DE69511449T2 (de) * 1994-04-15 2000-03-23 Takeda Chemical Industries Ltd Octahydro-2-Naphthalincarbonsäure-Derivate, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
HUP9802424A3 (en) 2003-02-28
CA2231143C (en) 2005-06-21
CN1101391C (zh) 2003-02-12
TR199800720T2 (xx) 1998-09-21
EP1106610A1 (en) 2001-06-13
JPH11514635A (ja) 1999-12-14
DK1019395T3 (da) 2002-05-06
SI1019395T1 (en) 2002-06-30
HK1036064A1 (en) 2001-12-21
NO980928D0 (no) 1998-03-04
ES2171736T3 (es) 2002-09-16
NO980928L (no) 1998-04-29
JP4257869B2 (ja) 2009-04-22
PL328230A1 (en) 1999-01-18
IL123567A (en) 2002-11-10
IL123567A0 (en) 1998-10-30
KR100417620B1 (ko) 2004-05-27
ATE269322T1 (de) 2004-07-15
AU712435B2 (en) 1999-11-04
AR004699A1 (es) 1999-03-10
DE69632751T2 (de) 2005-08-04
MX9802067A (es) 1998-08-30
US5968952A (en) 1999-10-19
CZ290954B6 (cs) 2002-11-13
CA2231143A1 (en) 1997-05-09
EA000719B1 (ru) 2000-02-28
EP1019395A1 (en) 2000-07-19
HUP9802424A2 (hu) 1999-10-28
TW349948B (en) 1999-01-11
DE69618999D1 (de) 2002-03-14
SK282642B6 (sk) 2002-10-08
PT1019395E (pt) 2002-07-31
HK1027576A1 (en) 2001-01-19
CY2287B1 (en) 2003-07-04
NO314037B1 (no) 2003-01-20
NZ321576A (en) 1999-05-28
WO1997016443A1 (en) 1997-05-09
CN1200732A (zh) 1998-12-02
ZA969087B (en) 1998-04-29
EP1106610B1 (en) 2004-06-16
CZ127298A3 (cs) 1998-12-16
DE69632751D1 (de) 2004-07-22
ATE212627T1 (de) 2002-02-15
MY116577A (en) 2004-02-28
ES2233557T3 (es) 2005-06-16
PL184168B1 (pl) 2002-09-30
AU7493396A (en) 1997-05-22
DE69618999T2 (de) 2002-09-26
HU224032B1 (hu) 2005-05-30
SK55698A3 (en) 1999-02-11
EP1019395B1 (en) 2002-01-30
KR19990063639A (ko) 1999-07-26

Similar Documents

Publication Publication Date Title
EA199800395A1 (ru) Производные 2-хинолона, ингибирующие фарнезилтрансферазу
EA199800443A1 (ru) (имидазол-5-ил) метил-2-хинолиноновые производные, ингибирующие фарнезилпротеин-трансферазу
EA200100708A1 (ru) 1, 2-аннелированные производные хинолина
AR102722A2 (es) Un derivado de pirazolo-quinazolina, su uso, un procedimiento para prepararlos, composiciones farmacéuticas que los comprenden, compuestos utilizables en su preparación, una biblioteca de dos o más compuestos, y un producto o kit
NO994268D0 (no) Farnesyltransferase-inhiberende 1,8-annelerte kinolinonderivater substituert med N- eller C-bundede imidazoler
NO308736B1 (no) 1,2-difenylpyrrolderivater, farmasøytiske preparater inneholdende disse, og deres anvendelse
BR9803883A (pt) Derivado de amida.
TR199902606T2 (xx) Farnesil transferaz� engelleyici kinazolinonlar.
YU96103A (sh) Novi derivati indola sa afinitetom za 5-ht6 receptor
IL112462A0 (en) Substituted aromatic compounds
ATE206390T1 (de) Cyclobutan-derivate als inhibitoren der squalen- synthase und der protein farnesyltransferase
MY116542A (en) New inhibitors of platelet aggregation.
TR200400342T4 (tr) Farnezil protein transferazı önlemek için kinolin türevleri.
BR9811521A (pt) Composição para tratar ou impedir a glomerulopatia
IL111036A0 (en) Beta_alanine derivatives, processes for the preparon thereof and pharmaceutical compositions containing the same
BR9812922A (pt) Isoquinolinas como inibidores de uroquinase
ID23954A (id) Tetrahidrogama-karbolin
HUP0301551A2 (hu) 5-HT3 és idegi nikotinsav receptor antagonista 1-amino-alkil-ciklohexán származékok új alkalmazása
FR2672801B1 (fr) Utilisation de derives de tetrahydrothienopyridine comme inhibiteurs de l'angiogenese.
AP9701010A0 (en) Piperidineacetic acid derivatives useful as fibrinogen.
BR0008778A (pt) Análogos de prostaglandinas seletivos para fpc16 insaturados
IL112630A (en) Derivatives of (2-(ar)alkyldithioindane-2-carboxamido) tricyclic-oxobenzazepine and similar compouds useful as inhibitors of enkephalinase, their preparation and pharmaceutical compositions containing them
PT1351954E (pt) Derivados 4-heterociclil-quinolina e quinazolina inibidores da farnesil-transferase
NO973242L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av idiopatisk eller fysiologisk gynekomasti
NO973341L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for vasodilatorisk behandling eller profylakse

Legal Events

Date Code Title Description
MK4A Patent expired

Designated state(s): RU